SCHEMBL1130987

SCHEMBL1130987

Cn1ccc2c(C(=O)O)cccc21

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 1/20 0.61
TUBB4A P04350 1/20 0.54
TUBB P07437 1/20 0.54
TUBA3C P0DPH7 1/20 0.54
TUBA1B P68363 1/20 0.54
TUBA4A P68366 1/20 0.54
TUBB4B P68371 1/20 0.54
TUBB3 Q13509 1/20 0.54
TUBB2A Q13885 1/20 0.54
TUBB8 Q3ZCM7 1/20 0.54
TUBA3E Q6PEY2 1/20 0.54
TUBA1A Q71U36 1/20 0.54
TUBA1C Q9BQE3 1/20 0.54
TUBB6 Q9BUF5 1/20 0.54
TUBB2B Q9BVA1 1/20 0.54
TUBB1 Q9H4B7 1/20 0.54
POLB P06746 1/20 0.47
NQO2 P16083 1/20 0.46
NR4A2 P43354 2/20 0.46
NR4A1 P22736 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30251521 1.00 PTPN1 (0.61) PTPN1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL4985228 0.86 PTPN1 (0.55) PTPN1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL3923460 0.85 TUBB4A (0.54) PTPN1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL4109141 0.84 TUBB4A (0.52) PTPN1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL701556 0.81 NR4A2 (0.64) PTPN1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL31607540 0.81 NR4A2 (0.64) PTPN1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL19903102 0.81 TUBB4A (0.50) PTPN1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL2747728 0.80 HDAC3 (0.52) PTPN1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL28265649 0.80 TUBB4A (0.52) PTPN1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL8069501 0.79 BRD4 (0.51) PTPN1NR4A2NR4A1NR4A3LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102083827-A Thiazolidine compounds as orexin receptor antagonists ACTELION PHARMACEUTICALS LTD 2011-06-01 CN claimed
US-20110105491-A1 THIAZOLIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD. (CH) 2011-05-05 US claimed
EP-2155739-B1 2-CYCLOPROPYL-THIAZOLE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2010-10-06 EP claimed
US-20100222328-A1 2-CYCLOPROPYL-THIAZOLE DERIVATIVES ACTELION PHARMACEUTICALS LTD. (CH) 2010-09-02 US claimed
US-20100222396-A1 4-ARYL-BUTANE-1,3-DIAMIDES NOVARTIS AG (CH) 2010-09-02 US claimed
WO-2010086366-A1 4-ARYL-BUTANE-1,3-DIAMIDES NOVARTIS AG (CH) 2010-08-05 WO claimed
CN-101711247-A 2-cyclopropyl-thiazole derivatives ACTELION PHARMACEUTICALS LTD 2010-05-19 CN claimed
WO-2010038200-A1 OXAZOLIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2010-04-08 WO claimed
WO-2010004507-A1 THIAZOLIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2010-01-14 WO claimed
EP-3856179-B1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2026-05-13 EP disclosed
US-12577243-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2026-03-17 US disclosed
EP-3856178-B1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2026-03-11 EP disclosed
US-12570675-B2 Boronic acid compounds LG CHEM, LTD. (KR) 2026-03-10 US disclosed
EP-4682146-A1 COMPOSITION INCLUDING NOVEL PYRIDOINDOLE DERIVATIVE COMPOUND AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF NEURODEGENERATIVE DISEASES Neurotarge Co., Ltd. (KR) 2026-01-21 EP disclosed
US-5449787-A Antiserotonine agents KYORIN PHARMACEUTICAL CO., LTD. (JP) 1995-09-12 US disclosed
EP-0630893-A1 N,N'-DISUBSTITUTED AMIDE DERIVATIVE KYORIN PHARMACEUTICAL CO., LTD. (JP) 1994-12-28 EP disclosed
US-5084474-A Antagonist of 5-hydroxytryptamine receptors on nerves and useful for treatment of psychotic disorders, anxiety, and nausea and vomiting, compounds of imidazole GLAXO GROUP LIMITED (GB) 1992-01-28 US disclosed
US-5019586-A 5-Hydroxytryptamine Receptor Antagonists GLAXO GROUP LIMITED 1991-05-28 US disclosed
US-4918080-A ANXIOLYTIC AGENTS, ANTIEMETICS GLAXO GROUP LIMITED (GB) 1990-04-17 US disclosed
EP-0291172-A1 Ketone derivatives GLAXO GROUP LIMITED (GB) 1988-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105491-A1 THIAZOLIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, OXTR PTPN1 1286/4885TUBB4A 1087/4885TUBB 1349/4885
US-12570675-B2 Boronic acid compounds PSMB6, PSMB3, PSMB2 PTPN1 256/4885TUBB4A 3187/4885TUBB 2911/4885
US-12577243-B2 Monoacylglycerol lipase modulators MGLL, LPL, FAAH PTPN1 2976/4885TUBB4A 3091/4885TUBB 2419/4885
US-20100222396-A1 4-ARYL-BUTANE-1,3-DIAMIDES CYP11B2, CYP11B1, BBC3 PTPN1 1235/4885TUBB4A 300/4885TUBB 372/4885
US-20100222328-A1 2-CYCLOPROPYL-THIAZOLE DERIVATIVES HCRTR2, HCRTR1, NPY2R PTPN1 1114/4885TUBB4A 864/4885TUBB 743/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.